149 related articles for article (PubMed ID: 32007466)
1. Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival.
Itani N; Grogan N; Mott S; Phadke S
Clin Breast Cancer; 2020 Jun; 20(3):209-214. PubMed ID: 32007466
[TBL] [Abstract][Full Text] [Related]
2. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
3. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
[TBL] [Abstract][Full Text] [Related]
4. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
6. Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups.
Hu J; Fung MW; Tsang JY; Poon IK; Chan SK; Cheung SY; Hu H; Zhou D; Tse GM
Clin Breast Cancer; 2020 Jun; 20(3):253-261.e7. PubMed ID: 32205037
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
Caparica R; Richard F; Brandão M; Awada A; Sotiriou C; de Azambuja E
Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175
[TBL] [Abstract][Full Text] [Related]
8. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
[TBL] [Abstract][Full Text] [Related]
9. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
[TBL] [Abstract][Full Text] [Related]
10. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N
Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan.
Sawaki M; Yamada A; Kumamaru H; Miyata H; Nakayama K; Shimizu C; Miyashita M; Honma N; Taira N; Saji S
Breast Cancer; 2021 Jan; 28(1):1-8. PubMed ID: 33219915
[TBL] [Abstract][Full Text] [Related]
14. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
17. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
18. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
19. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
20. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]